Newsroom

Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.

At Novartis, we aim to be a leader in environmental sustainability and a catalyst for positive change both in our own operations and in our supply chain.

European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today.

Standing by people with sickle cell disease and their families

COVID-19 is disrupting Africa’s health services – potentially undermining decades of progress on child health.